Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (audit firm) for the company for the upcoming fiscal year. It details the background of the accounting firm, personnel involved, audit fees, and the approval process by the board and independent directors. It does not contain any financial statements or audit results itself, but rather is a formal announcement about the appointment of the auditor. The document length is 2919 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information such as auditor appointments, but not full annual reports or financial statements. FY 2022
2023-04-18 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司使用部分暂时闲置募集资金及自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from the sponsor institution (Guojin Securities Co., Ltd.) regarding the use of temporarily idle raised funds and self-owned funds by Wuxi Xiangsheng Medical Technology Co., Ltd. for cash management. It references regulatory guidelines related to the management and use of raised funds, includes detailed descriptions of the investment purpose, products, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. The document does not contain financial statements or quarterly/yearly financial results but is a regulatory compliance and verification report related to the use of raised funds. It is not an announcement of voting results, not a financial report like an annual or interim report, nor a call transcript or capital update. It fits best under Regulatory Filings (RNS) as a compliance and verification document related to fund usage and cash management, which does not fit other specific categories.
2023-04-18 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2022年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导跟踪报告" (2022 Annual Continuous Supervision Follow-up Report) issued by Guojin Securities Co., Ltd. as the sponsor institution for Wuxi Xiangsheng Medical Technology Co., Ltd. It references regulatory frameworks related to securities issuance and listing supervision, continuous supervision work, risk factors, financial data for 2022, and compliance with fundraising usage. The document contains detailed financial data, risk disclosures, and compliance information for the year 2022. It is not an announcement of a report but a substantive supervisory follow-up report with financial and operational details. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone supervisory and audit-related report distinct from a full Annual Report (10-K). It is not a regulatory filing or announcement, nor a management report or earnings release. Therefore, the best fit is AR with high confidence. FY 2022
2023-04-18 Chinese
祥生医疗关于2022年年度利润分配方案的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the 2022 annual profit distribution plan of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the proposed cash dividend per share, the total dividend amount, and the approval process including board and supervisory committee meetings. It explicitly states that the profit distribution plan will be submitted to the 2022 annual shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details and related corporate governance approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2023-04-18 Chinese
无锡祥生医疗科技股份有限公司2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the period January to March 2023. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. The document is over 11,000 characters, so it is not a mere announcement or publication notice. There is no indication that this is an annual report, audit report, or any other filing type. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2023-04-18 Chinese
祥生医疗独立董事关于第二届董事会第十八次会议相关议案的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding specific proposals to be considered at the company's board meeting. It references compliance with regulatory guidelines and company rules, and it specifically addresses the appointment of the 2023 audit firm and anticipated related party transactions for 2023. The document does not contain financial statements or detailed financial data but rather expresses pre-approval or endorsement of agenda items for the board meeting. The document length is short (1183 characters), and it is clearly a management or board-related announcement rather than a full report or audit document. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2023-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.